会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • METHOD AND SYSTEM FOR IDENTIFYING, ASSESSING, AND MANAGING CANCER GROWTH RATES AND POTENTIAL METASTASIS
    • 识别,评估和管理癌症生长率和潜在的细胞因子的方法和系统
    • US20130071333A1
    • 2013-03-21
    • US13623098
    • 2012-09-19
    • Larry PARTAINMingshan SUNEdward J. SEPPIRaisa PAVLYUCHKOVAArundhuti GANGULYStavros PRIONASJames E. CLAYTON
    • Larry PARTAINMingshan SUNEdward J. SEPPIRaisa PAVLYUCHKOVAArundhuti GANGULYStavros PRIONASJames E. CLAYTON
    • A61K49/04
    • G06F19/3431G06F19/00G06K9/6277G06K2209/053G16H50/30
    • Techniques described herein generally relate to identifying, assessing, and managing cancer growth rates and potential metastasis. Some example methods may include constructing one or more quantitative metrics for the potential metastasis in a selected population of other patients, acquiring a first set of numeric biomarker data for the patient before having placed a biomarker in the patient, acquiring a second set of numeric biomarker data for the patient after having placed the biomarker in the patient, determining a set of biomarker surrogate values for microvessel density information based on a mean numeric biomarker difference derived from the first set of numeric biomarker data and the second set of numeric biomarker data, determining a set of biomarker surrogate values for microvessel density information based on a mean numeric biomarker difference derived from the first set of numeric biomarker data and the second set of numeric biomarker data, and predicting quantitative and objective risk for the cancer growth rates and potential metastasis and adjusting a treatment plan based on the biomarker surrogate values and at least one of the one or more quantitative metrics.
    • 本文描述的技术通常涉及鉴定,评估和管理癌症生长速度和潜在转移。 一些示例性方法可以包括为所选择的其他患者群体中的潜在转移构建一个或多个定量度量,在将患者的生物标志物置于患者体内之前获取患者的第一组数值生物标志物数据,获取第二组数值生物标志物 基于从第一组数字生物标志物数据和第二组数值生物标志物数据导出的平均数值生物标志物差异,确定用于微血管密度信息的生物标记替代值的集合,确定患者的数据;确定 基于从第一组数值生物标志物数据和第二组数值生物标志物数据得出的平均数值生物标志物差异的微血管密度信息的一组生物标志物替代值,并预测癌症生长速率和潜在转移的定量和客观风险, 根据生物标志物代理调整治疗计划 值和至少一个一个或多个定量度量。